Viatris completes acquisition of Pacira BioSciences
Viatris has closed its tender offer to buy Pacira for $36.50 per share. The deal enhances its portfolio in non-opioid pain management.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed